Skip to main content

Together we are beating cancer

Donate now

Tim Gunn

Tim is a digital news manager at Cancer Research UK. He started writing about science after studying English literature at Cambridge and magazine journalism at City, University of London. Before joining the digital news team in August 2022, he was a journalist and medical magazine editor.
Showing 12 out of 95 results
An African elephant walking along a dirt track

For World Elephant Day, we're taking a look at why elephants so rarely get cancer. Could the ways they protect themselves help people too? For World Elephant Day, we're taking a look at why elephants so rarely get cancer. Could the ways they protect themselves help people too?

by Tim Gunn | Analysis | 12 August 2023

12 August 2023

Aneurin Bevan, founder of the NHS, visits a patient on the service's first day.

To celebrate 75 years of the NHS, we’ve put together a timeline showing some of its biggest contributions to cancer care.   To celebrate 75 years of the NHS, we’ve put together a timeline showing some of its biggest contributions to cancer care.  

by Tim Gunn | In depth | 5 July 2023

5 July 2023

A transgender woman in a hospital gown speaking to her doctor, a transgender man, in an exam room.

Charities, research institutes and health providers across the UK are working to improve LGBTQIA+ cancer care. Here's how. Charities, research institutes and health providers across the UK are working to improve LGBTQIA+ cancer care. Here's how.

by Tim Gunn | Analysis | 23 June 2023

23 June 2023

Lung cancer cells seen through a microscope.
  • Science & Technology
  • Health & Medicine

ASCO 2023 roundup: Blood tests, drugs and exercise

ASCO’s annual meeting is the world’s biggest cancer conference. This year’s highlights included updates on cancer blood tests, AI tools for estimating cancer risk, better drugs for some lung and ovarian cancers, and interesting data on how yoga can help patients. ASCO’s annual meeting is the world’s biggest cancer conference. This year’s highlights included updates on cancer blood tests, AI tools for estimating cancer risk, better drugs for some lung and ovarian cancers, and interesting data on how yoga can help patients.

12 June 2023

Senedd Cymru, or the Welsh Parliament.

Health inequalities in Wales put deprived communities more at risk of cancer. The All Things Being Equal inquiry shows what has to change. Health inequalities in Wales put deprived communities more at risk of cancer. The All Things Being Equal inquiry shows what has to change.

by Tim Gunn | News | 8 June 2023

8 June 2023

Andrea receiving chemotherapy.

Chemotherapy-induced peripheral neuropathy (CIPN) is caused by cancer treatment, but there's no way to treat it. Our work is changing that. Chemotherapy-induced peripheral neuropathy (CIPN) is caused by cancer treatment, but there's no way to treat it. Our work is changing that.

by Tim Gunn | In depth | 22 May 2023

22 May 2023

A magnified image of squamous cell carcinoma, the most common type of cervical cancer

The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland. The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland.

by Tim Gunn | News | 16 May 2023

16 May 2023

Lab equipment at our Experimental Cancer Medicine Centre in Southampton
  • Science & Technology
  • Health & Medicine

3 ways we're helping teenagers and young adults with cancer

Teenagers and young adults with cancer have to deal with unique challenges. We're using our expertise to help tackle them. Teenagers and young adults with cancer have to deal with unique challenges. We're using our expertise to help tackle them.

by Tim Gunn | In depth | 18 April 2023

18 April 2023

Breast cancer cells

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

by Tim Gunn | News | 11 April 2023

11 April 2023

Fatimah, 19, near her home, and Adam, 23, on holiday. They were both diagnosed with cancer in their mid-teens.

For Teenage and Young Adult Cancer Awareness Month, we're hearing from four supporters who've faced the unique challenges of teenage cancer. For Teenage and Young Adult Cancer Awareness Month, we're hearing from four supporters who've faced the unique challenges of teenage cancer.

by Tom Bourton, Tim Gunn | Personal stories | 6 April 2023

6 April 2023

A scientist handling patient samples at an experimental cancer medicine centre.

We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people. We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people.

by Tim Gunn | In depth | 3 April 2023

3 April 2023